October 20, 2017

October 20, 2017


Cutting-edge gene therapy treatment approved for another deadly cancer; 1st for adults
Pittsburgh Post-Gazette – Oct. 20

Kite’s “vein-to-vein” turnaround period - from cell extraction to reinfusion - is about 17 days, according to Frederick Locke, an oncologist at Moffitt Cancer Center in Tampa and co-leader of the Kite trial.

Fighting Cancer with Friends, Family and God
The Weekly Challenger – Oct. 20

A support group member advised her to get a second opinion. A doctor at Moffitt Cancer Center suggested a far less radical treatment. She took his advice and remained cancer free for two years. On the third year she learned it had returned.

Second Gene Therapy Treatment for Blood Cancer Wins FDA Approval
CBS News – Oct. 19

At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. Locke helped run patient tests of Yescarta.

U.S. regulators approve 2nd gene therapy for aggressive lymphoma
Lawrence Journal-World – Oct. 19

At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. Locke helped run patient tests of Yescarta

With rebranded name, Innovation Place hosts annual event
Tampa Bay Times – Oct. 19

Innovation Place, or !p for short, will host the event and are packing 90 minutes of high-powered mixing and mingling with innovators from across Tampa Bay. The nonprofit represents 25,000 acres in the northern part of Tampa, bound by Busch Boulevard on the south, Bearss Avenue on the north, and interstates 75 and 275 on the east and west. It encompasses Busch Gardens, the University of South Florida, Moffitt Cancer Center, Florida Hospital and more than 4,000 other companies.

US FDA approve second gene therapy for blood cancer
Health Medical Network – Oct. 19

At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. Locke helped run patient tests of Yescarta.

A revolutionary treatment could help more than 10,000 people living with largely untreatable cancer
Insider – Oct. 19

Dr. Fred Locke, an oncologist and researcher at Moffitt Cancer Institute in Tampa, Florida, estimates that there are more than 10,000 adults who might benefit from these treatments, whereas the pediatric approval was initial geared for only about600 patients a year. Moffitt has been working with CAR-T since 2015, helping run clinical trials for Kite Pharma, the company that developed Yescarta that has since been acquired by Gilead Sciences.

US regulators approve 2nd gene therapy for blood cancer
WPVI-TV 6 ABC – Oct. 19


At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. Locke helped run patient tests of Yescarta. US FDA approve second gene therapy for blood cancer Health Medical Network – Oct. 19 At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. Locke helped run patient tests of Yescarta.

FDA Approves Yescarta; First CAR T-cell Therapy for Lymphoma
Lymphoma News Today – Oct. 19

“With CAR T therapy, we are re-engineering a patient’s own immune system to detect and kill cancer cells, and the results have been impressive,” said Dr. Frederick L. Locke, MD, co-lead investigator of the ZUMA-1 clinical trial and vice chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, Florida.

Thumbs Up to Latest CAR T-Cell Therapy Approval
MedPage Today – Oct. 19

More than 10,000 patients die of DLBCL each year, and axi-cel could have an almost immediate impact on that mortality, said Frederick Locke, MD, of Moffitt Cancer Center in Tampa, Florida.

The FDA Just Approved a New Way of Fighting Cancer Using Personalized Gene Therapy
TIME Magazine – Oct. 19

“We think this therapy is here to stay. It’s very different from chemo,” says Dr. Frederick Locke, research director and clinical director of immune cell therapy at Moffitt Cancer Center in Tampa. “This is a living, breathing therapy that we are putting back into the patient that can persist, and continue to fight against the cancer. It’s pretty amazing.”

FDA Approves Gene Therapy Tested In Boston To Treat Adults With Lymphoma
CBS Boston – Oct. 19

At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. Locke helped run patient tests of Yescarta.

FDA approves cutting-edge cancer treatment for ‘patients without hope’ after Boston studies
WHDH – Oct. 19

“This is really an exciting advance for patients without hope,” Dr. Frederick Locke told WESH. Lock is the director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, and helped run patient tests of the drug. Also posted on WSVN  

FDA approves cutting-edge cancer treatment in 'advance for patients without hope
WESH – Oct. 19

At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. Locke helped run patient tests of Yescarta. 

FDA Approves First Gene Therapy for non-Hodgkin Lymphoma
BioScience Technology – Oct. 19

“With CAR T therapy, we are reengineering a patient’s own immune system to detect and kill cancer cells, and the results have been impressive,” said Frederick L. Locke, MD, ZUMA-1 Co-Lead Investigator and Vice Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, Florida, in a statement. Also posted on Managed Care Magazine 

FDA approves axicabtagene ciloleucel CAR T cell therapy for relapsed B cell lymphoma
eCancer News – Oct. 19

With CAR T therapy, we are re-engineering a patient’s own immune system to detect and kill cancer cells, and the results have been impressive,” said Frederick L. Locke, MD, ZUMA-1 Co-Lead Investigator and Vice Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, Florida. 

FDA approves second ever gene therapy to fight aggressive form of blood cancer
The Daily Mail – Oct. 19

At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. Locke helped run patient tests of Yescarta.

FDA Approves CAR T-Cell Therapy for Adults With Aggressive Lymphomas
Cancer Network – Oct. 19

“With CAR T therapy, we are re-engineering a patient’s own immune system to detect and kill cancer cells, and the results have been impressive,” said ZUMA-1 co-lead investigator Frederick L. Locke, MD, of the Moffitt Cancer Center in Tampa, Florida, in a press release.  

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
Nieuwsbank – Oct. 19

“With CAR T therapy, we are reengineering a patient’s own immune system to detect and kill cancer cells, and the results have been impressive,” said Frederick L. Locke, MD, ZUMA-1 Co-Lead Investigator and Vice Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, Florida. Also posted to CheckOrphan 

FDA Approves second gene-altering treatment for cancer
The New York Times – Oct. 18

“The results are pretty remarkable,” said Dr. Frederick L. Locke, a specialist in blood cancers at the Moffitt Cancer Center in Tampa, and a leader of a study of the new treatment. “We’re excited. We think there are many patients who may need this therapy.”

He added, “These patients don’t have other options.” 

Cutting-edge immunotherapy treatment approved for another deadly cancer
The Washington Post – Oct. 18

Kite's “vein-to-vein” turnaround period — from cell extraction to reinfusion — is about 17 days, according to Frederick Locke, an oncologist at Moffitt Cancer Center in Tampa and co-leader of the Kite trial. 

FDA approves 2nd gene therapy for blood cancer, this one for aggressive lymphoma in adults
Chicago Tribune – Oct. 18

"This is really an exciting advance for patients without hope," said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida.

US regulators approve 2nd gene therapy for blood cancer
Houston Chronicle – Oct. 19

At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. Locke helped run patient tests of Yescarta. 

FDA backs gene therapy for cancer
The Boston Globe – Oct. 19

“The results are pretty remarkable,” said Dr. Frederick L. Locke, a specialist in blood cancers at the Moffitt Cancer Center in Tampa and a leader of a study of the new treatment. “We’re excited. We think there are many patients who may need this therapy.” 

US Regulators Approve 2nd Gene Therapy For Blood Cancer
The Associated Press – Oct. 18

At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. Locke helped run patient tests of Yescarta. Also posted to the Florida Times Union, WSBTV, Newser, WOKV, TDS, TruVista, WindstreamPeoplePC, Midco 

Israeli-Founded Kite Pharma gets FDA nod for cancer therapy
The Times of Israel

“Now, thanks to this new therapy many patients are in remission for months,” said Frederick Locke, co-lead investigator and vice chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, Florida. 

FDA Approves Yescarta, Revolutionary CAR-T Immunotherapy for Non-Hodgkin's Lymphoma Patients
Pharmacy Choice – Oct. 18

The Food and Drug Administration announced today the approval of Yescarta? (Axicabtagene ciloleucel), a revolutionary new immunotherapy for adult patients with diffuse large B cell lymphoma, a form of non-Hodgkin's lymphoma. Yescarta is a Chimeric Antigen Receptor (CAR) T cell therapy, also known as CAR-T. Moffitt Cancer Center's Frederick Locke, M.D., is the co-lead investigator of the pivotal ZUMA-1 clinical trial that tested the new therapy, which is manufactured by Kite, a Gilead company. Also posted to USA Life Sciences, Renewable Energy World, Pittsburgh Post-Gazette, Press Release Point, DMN Newswire, Le Lezard 

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
Business Wire – Oct. 19

“With CAR T therapy, we are reengineering a patient’s own immune system to detect and kill cancer cells, and the results have been impressive,” said Frederick L. Locke, MD, ZUMA-1 Co-Lead Investigator and Vice Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, Florida. Also posted to Pipeline Review, IberoNews, KITVWBOC2, WTOL, WTOC, KTRE, WBRC, WVUE, KMOV, KASA, WICU, WSIL, Pittsburgh Post-Gazette, KVHP, WWBT, WBTV, WSFAWZVN, WLBT, KWTV, WDRB, WOHL, KSWO, WXIX, WOWK, WLOX, KWES, KFBB, Telemundo Amarillo, Health Technology Net, Digital Journal, KWYB, KULR, SWX, KTVN, KXXV, KTEN, KFVE, KPLC, KEYC, WBOY, KHQTV, WFXG, WOIO, KOTV, KFDA, KAUZ, WIS, KQCW, WLNE, KCTV, WVNS, KSLA, KFVS, WAFF, PublicNow, WTRF, KFMB, WAFB, Finanz Nachrichten, Financial, Stock Watch,

US $373,000 gene therapy approved for blood cancer
The Standard – Oct. 19

At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. Locke helped run patient tests of Yescarta.

FDA Oks new gene therapy for cancer
The Lewiston Tribune – Oct. 19

At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Fla. Locke helped run patient tests of Yescarta.

Cutting-edge immunotherapy treatment approved for another deadly cancer
The Denver Post – Oct. 18

Kite’s “vein-to-vein” turnaround period – from cell extraction to reinfusion – is about 17 days, according to Frederick Locke, an oncologist at Moffitt Cancer Center in Tampa and co-leader of the Kite trial. Also posted to the Pittsburgh Post-Gazette, Fierce Pharma

Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-cel nod
College and University – Oct. 18

Then, in May 2016, she received Kite’s CAR-T treatment at Moffitt Cancer Center in Florida. She was declared cancer-free at her six-month checkup and no longer requires any cancer treatment. “I feel like I have my life back—I’m able to do everything I did before,” said Revoir, a married mother of two grown daughters and retired graphics professional for the Greater Orlando Aviation Authority.

FDA approves 2nd gene therapy for blood cancer, this one for aggressive lymphoma in adults
Chicago Tribune – Oct. 18

At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. Locke helped run patient tests of Yescarta. 

FDA Approves Axi-Cel for Large B-cell Lymphoma
Targeted Oncology – Oct. 18

“With CAR T therapy, we are reengineering a patient’s own immune system to detect and kill cancer cells, and the results have been impressive,” ZUMA-1 co-lead investigator Frederick L. Locke, MD, vice chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center, said in a statement.  

FDA approves cutting-edge cancer treatment tested in Boston
WCVB – Oct. 18

At that point, patients are generally out of options and only have about a 10 percent chance of even temporary remission of their cancer, said Dr. Frederick Locke, director of research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. Locke helped run patient tests of Yescarta. Also posted to WMTW.

FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma
OncLive – Oct. 18

"It is important to note that the toxicities that we saw—CRS and neurological events—are generally reversible," lead investigator Frederick L. Locke, MD, medical oncologist at Moffitt Cancer Center, told OncLive at the 2017 AACR Annual Meeting. 

Dr. Shah Discusses Autologous Transplant in MCL
OncLive – Oct. 18

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, discusses autologous stem cell transplant (ASCT) in mantle cell lymphoma (MCL).

20th Annual BioFlorida Conference fuels the future of Florida’s life sciences
Renewable Energy World – Oct. 18

The 2017 recipient of the BioFlorida Lifetime Achievement Award was presented to H. Lee Moffitt, the founder of Moffitt Cancer Center. Also posted to the Pittsburgh Post-Gazette, The Street, Arizona Republic, KCBD,

Moffitt CEO Alan List, new chair of Tampa Hillsborough EDC, outlines goals for 2018
Tampa Bay Times – Oct. 18

Moffitt Cancer Center CEO Alan List was officially elected the 2018 chairman of the Tampa Hillsborough Economic Development Corp. at the EDC's annual meeting held Tuesday night at the Amalie Arena.  

Here are the priorities for the new Tampa Hillsborough EDC chair
Tampa Bay Business Journal – Oct. 18

Growing the life sciences industry is a key goal for Dr. Alan List, president and CEO of Moffitt Cancer Center and the new chairman of the Tampa Hillsborough Economic Development Corp. 

Breast Cancer Awareness
Orlando Times – Oct. 18

This is the fifth Breast Cancer edition that The Orlando Times newspaper has published and features information provided to our publication by way of Florida Hospital Cancer Institute, the Mayo Clinic, the Moffitt Cancer Center, the University of Florida Cancer Center at Orlando Health and national statistics compiled and researched by the editorial staff of The Orlando Times. 

20th Annual BioFlorida Conference Fuels the Future of Florida's Life Sciences
PR Newswire – Oct. 18

The 2017 recipient of the BioFlorida Lifetime Achievement Award was presented to H. Lee Moffitt, the founder of Moffitt Cancer Center. 

Overall survival up for melanoma brain metastases
Medical Xpress – Oct. 18

Sarah Sloot, M.D., from Groningen University Medical Center in the Netherlands, and colleagues identified 610 patients with unresectable American Joint Committee on Cancer stage III/IV melanoma who received first-line systemic therapy at Moffitt Cancer Center between 2000 and 2012.

Geriatric Oncology Resources
ASCO – Oct. 18

The Moffitt Cancer Center’s Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) Score Calculator categorizes older patients with cancer into one of four risk areas of severe toxicity from chemotherapy: low, medium-low, medium-high, and high.  

ctDNA EGFR Testing Identifies Proper Patients for Frontline Osimertinib
OncLive – Oct. 17

“These results support the clinical utility of plasma ctDNA EGFRmutation testing for selecting patients eligible for first-line osimertinib treatment,” said Jhanelle E. Gray, MD, a medical oncologist and the director of clinical research in the Department of Thoracic Oncology at H. Lee Moffitt Cancer Center and Research Institute. 

Proscia Announces Newly Formed Board of Advisors
PR Web – Oct. 17

Anthony M. Magliocco, MD, FRCPC, FCAP. Dr. Magliocco is a Board Certified molecular and anatomical pathologist. He is currently Chair of Anatomic Pathology and Executive Director of Esoteric Laboratory Services at the Moffitt Cancer Center. He also serves as the Scientific Director of the Moffitt Tissue Core. 

Trigaux: Campaign aims to leverage tourism ads to recruit millennials, businesses
Tampa Bay Times – Oct. 16

Scientist Ruan Cox: "I'm from Miami. I came to Tampa Bay in 2009 for graduate school at USF's College of Medicine, pursuing a Ph.D. in biomedical sciences. I'm excited to be here because I have the pleasure of working at the Moffitt Cancer Center. Making a difference in the lives of others by helping to discover innovative cancer treatments motivates me to go to work each day." 

Moffitt Team Uses Proteomic Profiling to ID New Ceritinib Targets in Lung Cancer
GenomeWeb – Oct. 16

Researchers at the H. Lee Moffitt Cancer Center and Research Institute have used a chemical proteomic and phosphoproteomics-based approach to explore the molecular mechanisms underpinning the function of the anaplastic lymphoma kinase inhibitor ceritinib in lung cancer.

Finger pointing since passage of Florida’s medical marijuana law
News 965 – Oct. 16

  • Engaged Moffitt Cancer Center regarding their requirements under SB 8-A and is currently working toward finalizing an agreement with the organization.  

AstraZeneca shares its comprehensive scientific approach at the World Conference on Lung Cancer 2017
Press Release Point – Oct. 16

Jhanelle Gray, MD, Medical Oncologist and Director of Clinical Research in the Department of Thoracic Oncology at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, said: “Testing continues to be a critical part of lung cancer care, but the rapid development and evolution of multiple testing modalities and platforms can be challenging for physician teams to manage. Continued understanding of how assays compare builds confidence in treatment decisions, leading to better patient outcomes” Also posted to 4-Traders, PublicNow, MyNewsdesk 

ASTRO presents awards to several researchers
Healio – Oct. 15

The Annual Meeting Travel Award recognizes outstanding research by early-career scientists, biologists and physicists. Recipients were: … George Grass, MD, PhD, of Moffitt Cancer Center 

FDA approved drug found to have anti-cancer activity against previously unknown targets
Gears of Biz – Oct. 14

A team of researchers at Moffitt Cancer Center used cellular drug screening, functional proteomics and computer-based modeling to determine whether drugs with well-known targets may be repurposed for use against other biological targets. 

Breast Cancer Awareness Charity Auction
Buccaneers.com – Oct. 13

All proceeds from the auction will go directly to Moffitt Cancer Center’s Foundation, which was established to support cancer research, patient care and education initiatives, focused on pioneering breakthroughs for the future that promise greater progress in saving lives and reducing cancer to a highly treatable illness.

Researchers learn more about toxic side effects of T-cell therapy pioneered at CHOP, Penn
The Philadelphia Inquirer – Oct. 13

That review was based on 100 patients treated at MD Anderson, Moffitt Cancer Center in Tampa, the Sylvester Cancer Center at the University of Miami and the Mayo Clinic Cancer Center in Rochester, Minn.

###

Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.